MedTrace Logo

Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia

NCT00668135 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2014-12-17

No results posted yet for this study

Summary

To demonstrate the efficacy, safety and tolerability of 10 mg oral vardenafil (BAY 38-9456) compared to placebo for a period of 12 weeks in men with erectile dysfunction (ED)

Conditions

Interventions

DRUG

Vardenafil (Levitra, BAY38-9456)

Vardenafil 10 mg orally on demand prior to intercourse

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2004-04-30
Completion
2004-04-30

Countries

  • Hong Kong
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00668135 on ClinicalTrials.gov